Semorinemab
- Generic Name
- Semorinemab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2159141-27-0
- Unique Ingredient Identifier
- O8DG8VI95O
- Background
Semorinemab is under investigation in clinical trial NCT03289143 (A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT03828747
- Locations
- 🇺🇸
Miami Jewish Health Systems, Miami, Florida, United States
🇺🇸Pharmacology Research Institute, Los Alamitos, California, United States
🇺🇸Collier Neurologic Specialists, Naples, Florida, United States
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 457
- Registration Number
- NCT03289143
- Locations
- 🇵🇱
M.A. - LEK A.M.Maciejowscy SC., Katowice, Poland
🇵🇱Novo-Med Zielinski i wspolnicy Sp. j., Katowice, Poland
🇵🇱AMED Medical Center, Warszawa, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath